The Patent Finder

Woodward Specialty LLC

22 patents currently held · Updated Nov 19, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Jul 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 4, 2027
    The maintenance fee for Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's disease (US 11,690,819) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
  • 2 fees due Feb 22 to 25, 2027 · next Feb 22
  • 2 fees due Mar 12 to 19, 2027 · next Mar 12
  • 1 fee due Jun 17, 2027
    The maintenance fee for Nasal Drug Delivery Device (US 10,507,295) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
  • 3 fees due Jul 21 to 23, 2027 · next Jul 21
  • 1 fee due Aug 6, 2027
    The maintenance fee for Nozzles for Nasal Drug Delivery (US 11,890,412) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,893,025Use of Growth Hormone Releasing Factor Analogs in Treating Patients Suffering from Wasting
In force
 · High confidence
In forceHigh confidence
US 9,114,086Coated Tablets of Eszopiclone
In force
 · High confidence
In forceHigh confidence
US 9,550,036Nasal Drug Delivery Device
In force
 · High confidence
In forceHigh confidence
US 10,507,295Nasal Drug Delivery Device
In force
 · High confidence
In forceHigh confidence
US 10,940,278Nozzles for Nasal Drug Delivery
In force
 · Medium confidence
In forceMedium confidence
US 11,890,412Nozzles for Nasal Drug Delivery
In force
 · Medium confidence
In forceMedium confidence
US 11,007,332Nozzles for Nasal Drug Delivery
In force
 · Medium confidence
In forceMedium confidence
US 8,871,713Formulations of Growth Hormone Releasing Factor (GRF) Molecules with Improved Stability
In force
 · High confidence
In forceHigh confidence
US 9,919,117Nozzles for Nasal Drug Delivery
In force
 · Medium confidence
In forceMedium confidence
US 11,191,910Medical Unit Dose Container
In force
 · High confidence
In forceHigh confidence
10 of 22 patents shown.
Pro members see all 22.
Pro members: see all 22 patents
Also on record, not counted in the 22: 8 lapsed for an unpaid fee · 9 ended at full term · 2 past the fee grace period. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited